ST. LOUIS--(BUSINESS WIRE)--Stereotaxis, Inc. (NASDAQ: STXS) announced today that the results of the Study to Obliterate Persistent Ventricular Tachycardia (STOP-VT) was presented at the European Society of Cardiology (ESC) 2011 Congress held in Paris, France on Sunday, August 28.
The STOP-VT study is the first-ever, prospective multicenter evaluation of magnetic navigation for VT ablation. The trial, led by Assoc. Prof. Petr Neuzil, MD, PhD, Head of Cardiology and Director of the Cardiac Arrhythmia Service at the Na Homolce Hospital in Prague, Czech Republic was conducted at four of the world’s most prominent arrhythmia treatment centers, including, Hospital of the University of Pennsylvania, Indiana University School of Medicine, and Na Homolce Hospital, University of Leipzig. Fifty-three patients with previous severe heart disease were treated with ventricular tachycardia (VT) with the Stereotaxis Robotic Ablation System. The acute success rate in the study was an impressive 94 percent, and no patients suffered a major complication. The acute success results obtained from the STOP-VT study are 10-15 percent higher than similar published studies using conventional ablation techniques.
“VT is one of the most challenging arrhythmia facing electrophysiologists due to complex anatomy, the sensitive nature of ventricular tissue, and potentially lethal outcomes,” said Prof Neuzil. “Catheter ablation of VT, one of the fastest growing EP procedures globally, requires the delivery of robust lesions for clinical success. The main advantage of Stereotaxis for treatment of ventricular tachycardia is the precise mapping and identification of the critical diseased portions of the heart that allows physicians to perform ablation in a more effective way. The results of the trial exceeded our expectations, both in terms of acute outcomes as well as overall safety.”
Prof Neuzil presented the STOP-VT data at ESC 2011 on Sunday, August 28. Due to the significance of the study, Prof Neuzil also discussed the study at an ESC press conference on Monday, August, 29, “Arrhythmias in the Real World.”
“VT is a potentially lethal heart rhythm disorder that requires highly precise mapping and effective lesion delivery for successful treatment,” said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. “The significant placement of the STOP-VT study results at the world’s largest cardiology meeting reinforces the exceptional value that Stereotaxis brings to this complex life-saving procedure.”
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.
Stereotaxis’ Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.
The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.